A Phase 1 study of GSK5764227 in participants with advanced solid tumors

2024-513663-10-01 Protocol 223054 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 17 Sep 2025 · Status Ongoing, recruiting · 3 EU/EEA countries · 17 sites · Protocol 223054

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 536
Countries 3
Sites 17

Neoplasms

Key facts

Sponsor
Glaxosmithkline Research & Development Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
17 Sep 2025 → ongoing
Decision date (initial)
2025-08-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-513663-10-01
ClinicalTrials.gov
NCT06551142

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Neoplasms

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Glaxosmithkline Research & Development Limited

Sponsor organisation
Glaxosmithkline Research & Development Limited
Address
79 New Oxford Street
City
London
Postcode
WC1A 1DG
Country
United Kingdom

Scientific contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

3 EU/EEA countries · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 60 3
Italy Ongoing, recruiting 40 5
Spain Ongoing, recruiting 60 9
Rest of world
Canada, Korea, Republic of, United Kingdom, Taiwan, Japan, Panama, Hong Kong, Israel, United States, Argentina
376

Investigational sites

France

3 sites · Ongoing, recruiting
Institut Bergonie
Departement d'Oncologie Medicale, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Leon Berard
Departement de Cancerologie Medicale, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
Departement Innovations Therapeutiques et Groupe Oncologie Genito-Urinaire, 114 Rue Edouard Vaillant, 94800, Villejuif

Italy

5 sites · Ongoing, recruiting
Centro Ricerche Cliniche Di Verona S.r.l.
Centro Ricerche Cliniche di Verona, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
IRCCS Istituto Nazionale Tumori Fondazione Pascale
S.C. Sperimentazioni Cliniche, Via Mariano Semmola 52, 80131, Naples
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unità Operativa di Fase 1, Largo Francesco Vito 1, 00168, Rome
Humanitas Mirasole S.p.A.
Phase I Clinical Trial Unit, Via Alessandro Manzoni 56, 20089, Rozzano
Istituto Europeo Di Oncologia S.r.l.
Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative, Via Giuseppe Ripamonti 435, 20141, Milan

Spain

9 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncología Médica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Clinic De Barcelona
Oncología, Unidad de Ensayos Clínicos de Fase Temprana, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Y Politecnico La Fe
Oncología Médica, Avenida Fernando Abril Martorell 106, 46026, Valencia
Hospital Universitario Virgen De La Victoria
Oncología, IBIMA Unidad de Fase 1, Calle Del Arroyo Teatinos S/N, 29010, Malaga
Hospital Universitario 12 De Octubre
Oncología Médica, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario De Badajoz
Oncología Médica, Avenida Elvas S/n, 06006, Badajoz
Hospital Universitario Fundacion Jimenez Diaz
Oncología, Unidad de Fase 1, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Clinico Universitario Lozano Blesa
Oncología Médica, Avenida De San Juan Bosco 15, 50009, Zaragoza
Hospital Universitario Ramon Y Cajal
Oncología Médica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-09-17 2025-09-17
Italy 2025-12-10 2025-12-10
Spain 2025-09-23 2025-09-23

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-14 Italy Acceptable
2025-08-11
2025-08-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-14 Italy Acceptable
2025-08-11
2025-10-14
3 SUBSTANTIAL MODIFICATION SM-2 2025-10-31 Italy Acceptable
2026-02-18
2026-02-19